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Abstract
Urotensin-II controls ion/water homeostasis in fish and vascular tone in rodents. We hypothesised that common genetic
variants in urotensin-II pathway genes are associated with human blood pressure or renal function. We performed family-
based analysis of association between blood pressure, glomerular filtration and genes of the urotensin-II pathway
(urotensin-II, urotensin-II related peptide, urotensin-II receptor) saturated with 28 tagging single nucleotide polymorphisms
in 2024 individuals from 520 families; followed by an independent replication in 420 families and 7545 unrelated subjects.
The expression studies of the urotensin-II pathway were carried out in 97 human kidneys. Phylogenetic evolutionary analysis
was conducted in 17 vertebrate species. One single nucleotide polymorphism (rs531485 in urotensin-II gene) was associated
with adjusted estimated glomerular filtration rate in the discovery cohort (p = 0.0005). It showed no association with
estimated glomerular filtration rate in the combined replication resource of 8724 subjects from 6 populations. Expression of
urotensin-II and its receptor showed strong linear correlation (r = 0.86, p,0.0001). There was no difference in renal
expression of urotensin-II system between hypertensive and normotensive subjects. Evolutionary analysis revealed
accumulation of mutations in urotensin-II since the divergence of primates and weaker conservation of urotensin-II receptor
in primates than in lower vertebrates. Our data suggest that urotensin-II system genes are unlikely to play a major role in
genetic control of human blood pressure or renal function. The signatures of evolutionary forces acting on urotensin-II
system indicate that it may have evolved towards loss of function since the divergence of primates.
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Introduction
Urotensin-II (U-II) is an eleven amino-acid peptide first
extracted from neurophysis (neuro-secretory organ) of Goby fish
(Gillichthys mirabilis) [1]. Native to the Gulf of California, Goby fish
is known for its exceptional ability to withstand profound changes
in temperature and osmolality of the aquatic environment [2].
One of the mechanisms involved in Goby’s adaptation to rapidly
changing osmolality is U-II [3]. In response to alternations in the
salinity, fish modulate expression of U-II and its partner molecules
in gills epithelium, urinary bladder and intestine [4]. Up-
regulation of U-II pathway in Goby fish translates into inhibition
of NaCl transport in a concentration dependent manner [4].
These data indicate that U-II system contributes to fish
osmoregulation and ion-exchange; both of which are regulated
by the mammalian kidney.
In mammals including mouse, rat, dog, pig, marmoset,
cynomolgus monkey and human, U-II signaling pathway genes
are expressed in the kidney [5–10]. In fact, kidneys have been
hypothesised to act as a source of systemic production of U-II
[11,12]. Data from experimental models suggest that circulating
levels of U-II may influence renal function in rodents. Indeed, in
rats U-II associated not only with glomerular filtration rate (GFR)
(through influence on renal blood flow) but also with renal
natriuresis [13,14].
U-II also is the most potent mammalian vasoconstrictor in vitro
[5]. Elevated serum levels of U-II were linked to human
hypertension, impaired renal function and diabetes but the trials
of pharmacological inhibition of the system failed to provide
evidence of its utility in therapy of elevated blood pressure (BP)
[8,15–20].
Systematic genetic association analysis may not only illuminate
previously unexpected mechanisms underpinning biological pro-
cesses but may also help to explain conflicting data from
experimental models and in vitro physiological studies. However,
data from systematic genetic analysis of U-II pathway are not
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available. Indeed, previous association studies were conducted on
single functional polymorphic variants of this pathway and
suffered from small sample size, insufficient genetic coverage and
lack of appropriate replication [21–23].
Given the body of evidence (collected primarily from animal
experiments) we hypothesised that genetic variation in U-II system
on DNA and mRNA level may be associated with GFR and BP in
humans. Using a large sample of both families and biologically
unrelated individuals we conducted first systematic genetic analysis
of U-II system in relation to human BP and estimated GFR
(eGFR). This was followed by comparative expression analysis of
U-II pathway genes in the hypertensive and normotensive human
kidneys and evolutionary analysis of the system in vertebrates.
Materials and Methods
Genetic association study
Populations and phenotypes. The discovery cohort -
Genetic Regulation of Arterial Pressure of Humans in the
Community (GRAPHIC) Study consists of 2037 subjects from
520 white British pedigrees recruited from the general population
in Leicestershire (UK) [24].
A total of 3521 individuals from five populations were used as a
wet lab-based replication resource. We used two collections of
pedigrees - Silesian Hypertension Study (SHS) with 629 individ-
uals from 207 nuclear families recruited in Silesia (south of Poland)
[25] and 213 families (703 subjects) from Silesian Cardiovascular
Study (SCS) [26]. A total of 2189 biologically unrelated individuals
collected in the replication resource were derived from Young
Men Cardiovascular Association Study 1 (YMCA1) (n = 1157),
Young Men Cardiovascular Association Study 2 (YMCA2)
(n = 597) and SCS extension (n= 435) [26]. Additional in silico
replication was conducted in 5356 individuals from the Swiss
CoLaus Study [27].
All individuals were of white European ancestry.
Phenotyping of all individuals included taking clinical history
(using anonymous coded questionnaires), physical examination,
anthropometric measurements (weight, height) and biochemical
tests (serum level of creatinine).
Estimated glomerular filtration rate was calculated from serum
creatinine using Modification of Diet in Renal Disease (MDRD)
formula: GFR (mL/min/1.73 m2) = 1866(Serum creatini-
ne)21.1546(Age)20.2036(0.742 if female): in all individuals
.18years old [28].
24-hour urinary excretion of sodium and potassium were
available for individuals from the GRAPHIC Study.
In subjects from the GRAPHIC Study Ambulatory BP was
measured (at 30-minute intervals between 08:00 and 21:59 [day
time] and at 1-hour intervals between 22:00 and 07:59 [night
time]) using a Spacelabs 90207 monitor (Spacelabs, Wokingham,
UK) for approximately 26 hours. The first 2 hours of each
recording were excluded from further analysis [29].
Clinic BP was recorded in triplicate in a sitting position using
digital BP monitors (The GRAPHIC Study, SCS, CoLaus) or
sphygmomanometers (SHS, YMCA1 and YMCA2) with an
appropriate size cuff after necessary rest [30]. The results of all
3 measurements were averaged in SHS, SCS, YMCA1 and
YMCA2; in the GRAPHIC Study and CoLaus only second and
third measurements were averaged [27].
In GRAPHIC Study, SHS, and SCS the effect of antihyper-
tensive treatment on BP was corrected for using a semi-parametric
algorithm [31]. In brief, adjustment value is calculated by
subtracting the mean of the regression based residuals of treated
individuals from the mean residuals of non-treated subjects
(matched for BP readings). In individuals on treatment, treatment
adjusted BP value is then a sum of the measured BP and
adjustment value.
In CoLaus, YMCA1 and YMCA2 for individuals taking
antihypertensive therapies, blood pressure was imputed by adding
15 mm Hg and 10 mm Hg for systolic BP (SBP) and diastolic BP
(DBP), respectively [31].
Single nucleotide polymorphisms and genes of U-II
pathway. Three genes of the pathway – urotensin-II gene
(UTS2), urotensin-II related peptide gene (UTS2D) and urotensin-
II receptor gene (UTS2R) were selected for genetic association
analysis. A total of 28 tagging single nucleotide polymorphisms
(SNP) in these loci (16 in UTS2, 7 in UTS2D and 5 in UTS2R)
were chosen for genotyping in the GRAPHIC Study to capture
the common genetic variation under the following criteria: minor
allele frequency (MAF).0.05 and r2.0.8 (Figure 1). The detailed
description of SNPs of the pathway is in the Table S1 in file S1.
Genotypes of these SNPs in the discovery cohort (the GRAPHIC)
were partly derived from Illumina HumanCVD BeadChip (50K
IBC array) [32] or obtained through direct TaqMan-based DNA
analysis (on ABI PRISM 7900HT Sequence Detection System,
Applied Biosystems). The SNP taken forward for replication was
genotyped directly by TaqMan in SHS, SCS, YMCA1 and
YMCA2 or extracted in silico from the Affymetrix Genome-Wide
Human SNP Array used before in genome-wide analysis in
CoLaus (IMPUTE version 0.5, imputation coefficient of accuracy
0.94) [29,33]. The details of SNP selection and quality control
criteria are included in Tables S1 and S2 in file S1.
Statistical analysis. Heritability analysis of eGFR, clinic
SBP and DBP in 2 cohorts of families (GRAPHIC Study, SCS
families,) was performed using variance component analysis
algorithm implemented in SOLAR (Sequential Oligogenic Link-
age Analysis Routines) v2.0 software after adjustment for age, age2
and sex [34].
The primary analysis of genetic associations in families was
conducted using Family Based Association Test (FBAT). Associ-
ations between SNPs of the candidate pathway and age, age2, sex
and antihypertensive treatment (where appropriate) adjusted clinic
SBP, DBP, eGFR, 24 hour urinary sodium excretion, 24-hour
urinary potassium excretion, mean 24-hour SBP, mean 24-hour
DBP were examined under additive model of inheritance under
the null hypothesis of no linkage and no association. This method
of analysis is immune to population stratification [35]. Generalized
Estimating Equations (GEE) were then used to obtain quantitative
measures (b-coefficients and standard errors) of the detected
associations to facilitate the meta-analysis of the studies [36].
The analysis of association between U-II pathway SNP(s) in
cohorts of biologically unrelated subjects was performed using
PLINK-based [37] multiple linear regression model under additive
model of inheritance after adjustment for age sex and BP-lowering
effect of antihypertensive therapy (where appropriate).
In the discovery cohort the correction for multiple testing (28
SNPs and 7 phenotypes) was calculated using a spectral
decomposition of linkage disequilibrium statistics as proposed by
Nyholt [38]. Specifically, based on a calculated number of
independent genetic markers and phenotypes a threshold of
p = 0.0007 was calculated to keep type 1 error rate below 10%.
The details of this calculation are included in file S1.
Meta-analysis in all replication cohorts was conducted using a
fixed effect, inverse variance model implemented in Metan script
(STATA) [39]. Heterogeneity between studies was examined using
x2test.
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Gene expression analysis
U-II pathway gene expression was examined in two indepen-
dent collections of human kidneys: Silesian Renal Tissue Bank
(SRTB, n= 62, Poland) and the Western Poland Kidney Project
(WPKP, n= 35, Poland) [40,41]. Both collections come from well
phenotyped patients undergoing unilateral nephrectomy for non-
invasive renal cancer. A sample of human kidney tissue was
collected from unaffected by cancer (apparently healthy) pole of
the kidney and preserved in RNAlater (Ambion) and 270C prior
to gene expression studies. Each individual underwent phenotyp-
ing similar to the protocol used in SHS [40]. Hypertension was
defined as BP values $140/90 mmHg measured on at least two
separate occasions and/or taking anti-hypertensive medication.
Renal mRNA expression was quantified using designed Taq-
Man gene expression assays (Applied Biosystems) and normalized
to the expression of a housekeeping control gene (b-microglobu-
lin). All experiments were performed in duplicates. Multiple
regression models (with gene expression as a dependent variable
and age, sex, cohort and hypertension status) were used to
examine adjusted difference in gene expression between normo-
tensive and hypertensive subjects.
Evolutionary analysis
The analysis of evolutionary pressure acting on coding
sequences of U-II pathway genes was conducted using ratios of
non-synonymous to synonymous codon substitutions [42]. Synon-
ymous substitutions do not lead to changes in the amino acid
composition of a protein and are generally evolutionary neutral.
Non-synonymous substitutions lead to changes in the amino acid
composition of a protein and therefore provide an evolutionary
disadvantage or advantage for the carrier. DNA and peptide
sequences of UTS2, UTS2D and UST2R for all available
vertebrate species were obtained from ENSEMBL database
http://www.ensembl.org/index.html. Where more than one
splice variant was available, the longest was used as the reference
sequence. Multiple peptide sequences were aligned using
Teecoffee@igs web server (http://igs-server.cnrs-mrs.fr/Tcoffee/
tcoffee_cgi/i ndex.cgi) and manually inspected for accuracy [43].
Sequences missing the biologically important C-terminal frag-
ments of U-II or urotensin-II related peptide (URP) or sequences
substantially shorter than the average (introducing large gaps into
the alignment) were removed from further analysis. The ultimate
peptide alignments were used to guide complementary DNA
(cDNA) alignment using RevTrans 1.4 web server (http://www.
cbs.dtu.dk/services/RevTrans/) [44]. The cDNA alignments were
then used in evolutionary analysis conducted on Adaptive
Evolution Server (http://datamonkey.org). HKY85 nucleotide
substitution model was chosen using a genetic algorithm available
on http://datamonkey.org. Other parameters of the model
(substitution rates, codon frequencies and distances) were estimat-
ed using maximum likelihood procedures [45]. Phylogenetic line
specific evolutionary models were fitted using GABranch algo-
rithm available on http://datamonkey.org server.
Ethical approval
All subjects gave informed, written consent for participation and
the studies were approved by the appropriate Bioethical Com-
mittees. These were: Leicestershire Research Ethics Committee -
The GRAPHIC Study; Bioethical Committee of the Medical
University of Silesia - SHS, SCS, YMCA1, YMCA2, SRTB;
Institutional Ethics Committee of the University of Lausanne -
CoLaus; Bioethical Committee of the Karol Marcinkowski’s
Medical University in Poznan - WPKP.
Results
Demographic characteristics
The basic clinical characteristics of populations used in the
genetic association and gene expression analyses are presented in
Table 1.
Heritability analysis
Taking advantage of the availability of data from family cohorts
we estimated narrow-sense heritability for eGFR and BP in 733
families of white European ancestry. The age and sex adjusted
eGFR showed very significant heritable component ranging from
38.4% in the GRAPHIC Study (p= 5.5610225) to 46.5% in the
SCS families (p = 1.3610211) (Table 2). Both clinic SBP and clinic
DBP showed also substantial heritable component estimated in the
range of 30.5% (SBP in the GRAPHIC Study) to 47.1% (SBP in
SCS families) (Table 2).
Figure 1. Urotensin-II pathway genes and hypertension. Figure present structure of UTS2, UTS2D and UTS2R genes - linkage disequilibrium
(LD) map based on r2 coefficients [intensity of colour: r2 = 1 – maximal LD (dark red), r2 = 0 – no LD (white)] in the GRPAHIC Study.
doi:10.1371/journal.pone.0083137.g001
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Genetic association analysis
The GRAPHIC based analysis of 28 tagging SNPs (in UTS2,
UTS2D and UTS2R) and 7 phenotypes (eGFR, 24-hour urinary
sodium excretion, 24-hour urinary potassium excretion, mean 24-
hour SBP, mean 24-hour DBP, clinic SBP and clinic DBP) showed
that only one SNP (rs531485) was significantly associated with
eGFR after correction for multiple testing (p= 0.0005) (Tables S3–
S9 in file S1). This SNP was taken forward for replication and
genotyped directly in 2 family-based studies but showed no
association with eGFR in either (SCS families - p = 0.6779, SHS -
p= 0.6984) (Table 3). In cohorts of unrelated subjects rs531485
showed association with eGFR only in YMCA2 (p = 0.0130).
However, the direction of this association was opposite to the one
observed in the GRAPHIC Study. The rs531485 was not
associated with adjusted eGFR in the CoLaus study (p = 0.9019).
The meta-analysis of 8724 subjects from 6 populations showed no
association between rs531485 and eGFR (p= 0.5834) (Table 3).
Gene expression analysis
The expression of UTS2 and its receptor UTS2R showed
strong linear correlation in the human kidneys (r = 0.86,
P,0.0001) (Figure 2). Neither UTS2 and UTS2D nor UTS2D
and UTS2R showed significant linear correlation (r = 0.05,
P= 0.6312), (r = 0.18, P= 0.0875), respectively (Figure 2).
The comparative expression analysis of U-II system genes
between kidneys from normotensive and hypertensive subjects
(altogether 97 subjects) revealed no statistically significant differ-
ences (UTS2: p = 0.6447; UTS2D: p= 0.8733; UTS2R:
p= 0.1051) (Figure 2).
None of the 19 tagging SNPs genotyped in Silesian Renal
Tissue Bank (SRTB) showed association with expression of renal
mRNA of the relevant gene (Table S10 in file S1).
Evolutionary analysis
Line specific evolutionary analysis of pre-pro urotensin-II
sequences showed substantial differences across species with non-
synonymous (dN) to synonymous substitution (dS) ratios ranging
from 0.27 (strong conservation) to 1.6 (accumulation of mutations -
lack of conservation). There was a clear division between
phylogenetically older species and primates; they were separated
by long period of diversifying selection (Figure S1 in file S1).
Evolutionary analysis showed variable levels of purifying selection
acting on UTS2D and UTS2R with no evidence of periods of
diversifying selection (Figures S2 and S3 in file S1). Primates
exhibit relatively weakest purifying selection on UTS2R across
phylogeny.
Discussion
Our data show that common genetic variation in U-II pathway
is unlikely to play a major role in genetic regulation of human BP
or eGFR. There is a significant co-regulation between U-II and its
receptor in the human kidney but their expression is not associated
with hypertension. Additionally, our data suggests that biological
functions of U-II system may differ across species. This is
supported by our evolutionary analysis showing diversifying
selection (accumulating mutations) acting on the coding sequence
of U-II since the divergence of primates.
Our association study is the first systematic analysis of the role of
common variants in U-II system in regulation of human BP and
eGFR. The results of this analysis are in essence negative – the initial
signal of association between U-II and eGFR was not confirmed in
the replication study of 8724 subjects. Previous studies on association
between U-II system genes and cardiovascular phenotypes were
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performed on very small population samples and a majority of them
lacked independent replication [21–23]. Our analysis based on a total
of .10000 subjects is the largest association experiment on genetic
variants within U-II pathway genes to date.
The results of our gene expression experiments in SRTB and
Western Poland Kidney Project (WPKP) showed no evidence for
association of the pathway with human hypertension. To the best
of our knowledge this is the first gene expression analysis of the U-
II system of this scale (almost 100 human kidneys) and the first
direct comparative analysis of UTS2, UTS2D and UTS2R
expression in human tissue from normotensive and hypertensive
subjects. We confirmed that all three molecules of U-II pathway
were expressed in human kidney and that UTS2 and its receptor
(UTS2R) show strong correlation in expression. This suggests that
renal transcripts of UTS2 and UTS2R are under tight functional
co-regulation. A study by Matsushita et al. previously reported co-
expression of UTS2 and UTS2R in 5 samples taken from human
renal tissue [46]. This small sample size did not permit to confirm/
exclude the presence of co-regulation between both transcripts
[46]. No association between expression of U-II system in
hypertension in our study is in odds to findings from Cheung
et al. who showed raised plasma U-II levels in hypertensive
patients [16]. However, the value of measuring serum levels of U-
II by currently available radioimmunoassay has been questioned
[47].
Strong evolutionary conservation of the C-terminal cyclic
domain across different species was previously interpreted as an
evidence for the importance of U-II in physiology [48]. Our
evolutionary analysis showed very different signatures of evolution
acting on coding sequences of UTS2, UTS2D and UTS2R across
different species - dN/dS ratios ranged from 0.14 (purifying
selection) to 1.15 (accumulation of mutations). The evolutionary
pressures were weaker in UTS2 than UTS2D or UTS2R.
Stronger conservation of UTS2R than UTS2 is consistent with
its fundamental function in signaling of the pathway. UTS2
underwent a period of strong diversifying selection (accumulation
of amino-acid changes) following divergence of primates. Similar
trends are apparent in the analysis of UTS2R - purifying selection
in primates was weaker than in the phylogenetically older
vertebrates. Given the evolutionary difference, direct extrapolation
of results obtained from lower vertebrates to primates should be
made with caution. This could be supported by the presence of
differences between functioning of the system in different species;
e.g. rodent and primate UT act differently upon stimulation with
an artificial ligand; native and non-native U-II exerts different
effect on tissues [15,49,50].
Our data suggest that genetic variation within U-II system is not
associated with BP or eGFR in the population of white European
ancestry. The U-II system may play an important role in
phylogenetically older animals but it appears to have slowly
evolved towards loss of function since the divergence of primates.
Our data indicate that U-II pathway is an unlikely target for
further pharmacogenetic investigations.
Supporting Information
File S1 Tables S1–S10 and Figures S1–S3. Table S1. SNPs
in the U-II system genes - GRAPHIC Study. SNP – single
nucleotide polymorphism, UTS2 – urotensin-II gene, UTS2D –
urotensin-II related peptide gene, UTS2R – urotensin-II receptor
gene, Chr – chromosome, position – genetic position on
chromosome according to NCBI (CEU), MAF – minor allele
frequency, MA – minor allele, 39 – 39 untranslated region, 59 – 59
untranslated region, TaqMan – genotyping using TaqMan probes
Table 2. Blood pressure and estimated glomerular filtration rate – heritability analysis.
Cohort Heritability of eGFR Heritability of clinic SBP Heritability of clinic DBP
h2 (SE) P-value h2 (SE) P-value h2 (SE) P-value
GRAPHIC Study 0.384 (0.038) 5.5610225 0.305 (0.043) 2.5610213 0.317 (0.041) 2.2610215
SCS families 0.466 (0.069) 1.3610211 0.471 (0.074) 3.5610210 0.371 (0.080) 1.761026
h2 – narrow sense heritability, SE – standard error, P-value – level of statistical significance, GRAPHIC – Genetic Regulation of Arterial Pressure of Humans in the
Community, SCS – Silesian Cardiovascular Study, eGFR – estimated glomerular filtration rate, SBP – systolic blood pressure, DBP - diastolic blood pressure.
doi:10.1371/journal.pone.0083137.t002
Table 3. Association between eGFR and minor allele of rs531485 in urotensin-II gene – fixed effect inverse variance meta-analysis
in the replication resource.
Study Informative subjects b±SE P-value P-value*
SCS families 684 1.3461.11 0.2288
SHS 596 20.5460.73 0.4624
SCS replication panel 430 20.4260.95 0.6564
YMCA1 1119 20.0661.21 0.9612
YMCA2 539 23.2961.32 0.0130
CoLaus Study 5356 0.0460.35 0.9019
Meta-analysis 8724 20.15±0.28 0.5834 0.1494
SCS – Silesian Cardiovascular Study, SHS – Silesian Hypertension Study, YMCA – Young Men Cardiovascular Association Study, informative subjects – number of subjects
with available genotypic and phenotypic data, b – estimated effect size, SE – standard error of the estimate, P-value – level of statistical significance, P-value* - level of
the statistical significance in the x2 test of heterogeneity.
doi:10.1371/journal.pone.0083137.t003
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(Applied Biosystems), 50K IBC – genotyped using 50k Illumina
HumanCVD BeadChip. Table S2. Quality control of genotyping
in the GRAPHIC Study. SNP – single nucleotide polymorphism,
UTS2 – urotensin-II gene, UTS2D – urotensin-II related peptide
gene, UTS2R – urotensin-II receptor gene, Chr – chromosome,
position – genetic position on chromosome according to NCBI
(CEU), MAF – frequency of the minor allele (calculated in
parental generation for SCS families and SHS), HWE P-value –
the level of statistical significance in Hardy-Weinberg equilibrium
test. Table S3. Association between U-II system genes and
estimated glomerular filtration rate in the GRAPHIC Study.
SNP – single nucleotide polymorphism, ‘‘rs’’ – SNP identifier in
the NCBI, UTS2 – urotensin-II gene, UTS2D – urotensin-II
related peptide gene, UTS2R – urotensin-II receptor gene, MA –
minor allele, MAF – frequency of the minor allele in the parental
generation, Z – Z score – statistic calculated by the family-based
association test showing the direction of association, P-value – level
of statistical significance. Table S4. Association between U-II
system genes and log10 transformed 24-hour urinary sodium
excretion in the GRAPHIC Study. SNP – single nucleotide
polymorphism, ‘‘rs’’ – SNP identifier in the NCBI, UTS2 –
urotensin-II gene, UTS2D – urotensin-II related peptide gene,
UTS2R – urotensin-II receptor gene, MA – minor allele, MAF –
frequency of the minor allele in the parental generation, Z – Z
score – statistic calculated by the family-based association test
showing the direction of association, P-value – level of statistical
significance. Table S5. Association between U-II system genes and
log10 transformed 24-hour urinary potassium excretion in the
GRAPHIC Study. SNP – single nucleotide polymorphism, ‘‘rs’’ –
SNP identifier in the NCBI, UTS2 – urotensin-II gene, UTS2D –
urotensin-II related peptide gene, UTS2R – urotensin-II receptor
gene, MA – minor allele, MAF – frequency of the minor allele in
the parental generation, Z – Z score – statistic calculated by the
family-based association test showing the direction of association,
P-value – level of statistical significance. Table S6. Association
between urotensin-II system genes and mean 24-hour systolic
blood pressure in the GRAPHIC Study. SNP – single nucleotide
polymorphism, ‘‘rs’’ – SNP identifier in the NCBI, UTS2 –
urotensin-II gene, UTS2D – urotensin-II related peptide gene,
UTS2R – urotensin-II receptor gene, MA – minor allele, MAF –
frequency of the minor allele in the parental generation, Z – Z
score – statistic calculated by the family-based association test
showing the direction of association, P-value – level of statistical
significance. Table S7. Association between U-II system genes and
mean 24-hour diastolic blood pressure in the GRAPHIC Study.
SNP – single nucleotide polymorphism, ‘‘rs’’ – SNP identifier in
the NCBI, UTS2 – urotensin-II gene, UTS2D – urotensin-II
related peptide gene, UTS2R – urotensin-II receptor gene, MA –
minor allele, MAF – frequency of the minor allele in the parental
generation, Z – Z score – statistic calculated by the family-based
association test showing the direction of association, P-value – level
of statistical significance. Table S8. Association between U-II
system genes and clinic systolic blood pressure in the GRAPHIC
Study. SNP – single nucleotide polymorphism, ‘‘rs’’ – SNP
identifier in the NCBI, UTS2 – urotensin-II gene, UTS2D –
urotensin-II related peptide gene, UTS2R – urotensin-II receptor
gene, MA – minor allele, MAF – frequency of the minor allele in
the parental generation, Z – Z score – statistic calculated by the
family-based association test showing the direction of association,
P-value – level of statistical significance. Table S9. Association
between urotensin-II system genes and clinic diastolic blood
pressure in the GRAPHIC Study. SNP – single nucleotide
polymorphism, ‘‘rs’’ – SNP identifier in the NCBI, UTS2 –
urotensin-II gene, UTS2D – urotensin-II related peptide gene,
UTS2R – urotensin-II receptor gene, MA – minor allele, MAF –
frequency of the minor allele in the parental generation, Z – Z
Figure 2. Renal expression of Urotensin-II pathway genes. Upper panel - linear correlations in renal expression (dCT) of UTS2, UTS2D, and
UTS2R (r – correlation coefficient, p – level of statistical significance). Lower panel - comparison of UTS2, UTS2D and UTSR expression between
normotensive (bright grey) and hypertensive (dark grey) kidneys (p-values from multiple regression adjusted for age, sex and cohort of origin).
doi:10.1371/journal.pone.0083137.g002
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score – statistic calculated by the family-based association test
showing the direction of association, P-value – level of statistical
significance. Table S10. Association between SNPs in U-II
pathway genes and renal expression of UTS2, UTS2D and
UTS2R in kidneys from SRTB. SNP – single nucleotide
polymorphism, ‘‘rs’’ – SNP identifier in the NCBI, UTS2 –
urotensin-II gene, UTS2D – urotensin-II related peptide gene,
UTS2R – urotensin-II receptor gene, MA – minor allele, MAF –
frequency of the minor allele, b – effect size per each copy of
minor allele, SE – standard error, P-value – level of statistical
significance (adjusted for age and sex). Figure S1. Molecular
evolution of urotensin-II. Green lines represent periods of
diversifying selection with non-synonymous to synonymous
substitution ratio of 1.6 (accumulation of non-synonymous
mutations leading to changes in the protein sequence), orange
lines - moderate purifying selection with non-synonymous to
synonymous substitution ratio of 0.6; red lines – periods of strong
purifying selection with non-synonymous to synonymous substitu-
tion ratio of 0.27. Figure S2. Molecular evolution of urotensin-II
related peptide. Green lines represent periods of weak purifying
selection with non-synonymous to synonymous substitution ratio
of 0.6, orange lines represent strong purifying selection with non-
synonymous to synonymous substitution ratio of 0.2; red lines
represent periods of very strong purifying selection with non-
synonymous to synonymous substitution ratio of 0.03. Figure S3.
Molecular evolution of urotensin-II receptor. Green lines repre-
sent periods of moderately strong purifying selection with non-
synonymous to synonymous substitution ratio of 0.25, orange lines
represent moderate purifying selection with non-synonymous to
synonymous substitution ratio of 0.18; red lines represent periods
of very strong purifying selection with non-synonymous to
synonymous substitution ratio of 0.04.
(DOCX)
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